Literature DB >> 22374702

Metabolism and excretion studies of oral administered naringin, a putative antitussive, in rats and dogs.

Menghua Liu1, Wei Zou, Cuiping Yang, Wei Peng, Weiwei Su.   

Abstract

Naringin, a major active flavonone glycoside from a traditional Chinese medicine Huajuhong, has been demonstrated to have activities such as peripheral antitussive, mucoregulator and anti-inflammatory. The purpose of this study was to elucidate the metabolism and mass balance of orally administered naringin in rats and dogs. After oral administration of naringin to rats and dogs at doses of 42 mg/kg and 12.4 mg/kg, respectively, metabolites in excreta were identified using a LC-Q-TOF system. The major metabolites including naringin, total naringenin (including free naringenin and its conjugates) and 4-hydroxyphenylpropionic acid in excreta were quantified by a LC-MS/MS system. Twenty-two metabolites were identified in dogs and 17 metabolites were detected in rats. The observed routes of naringin metabolism were hydroxylation, methylation, acetylation, hydrogenation, deglycosylation, dehydrogenation, glucuronidation, sulfation, glucosylation, ring-fission, oxidation, glycine conjugation and dehydroxylation. On the basis of these identified metabolites, a comprehensive metabolic pathway of naringin was proposed. About 21% of administered naringin was recovered in rat excreta in the form of naringin, total naringenin and 4-hydroxyphenylpropionic acid, and about 60% was recovered in dog excreta. The levels of 4-hydroxyphenylpropionic acid in excreta were higher than those of naringin and total naringenin, and the quantified metabolites were excreted more through feces, rather than urine. Most of these metabolites were excreted within 36 h post dose. The results of metabolism and excretion studies provide an explanation for future pharmacological and toxicological findings and are the groundwork for clinical studies.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374702     DOI: 10.1002/bdd.1775

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  10 in total

1.  Identification of Naringin Metabolites in Human Urine and Feces.

Authors:  Xuan Zeng; Yang Bai; Wei Peng; Weiwei Su
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

2.  Binding interactions of naringenin and naringin with calf thymus DNA and the role of β-cyclodextrin in the binding.

Authors:  Sameena Yousuf; Israel V Muthu Vijayan Enoch
Journal:  AAPS PharmSciTech       Date:  2013-04-27       Impact factor: 3.246

3.  Assessment of the feed additive consisting of naringin for all animal species for the renewal of its authorisation (HealthTech Bio Actives, S.L.U. (HTBA)).

Authors:  Vasileios Bampidis; Giovanna Azimonti; Maria de Lourdes Bastos; Henrik Christensen; Birgit Dusemund; Mojca Fašmon Durjava; Maryline Kouba; Marta López-Alonso; Secundino López Puente; Francesca Marcon; Baltasar Mayo; Alena Pechová; Mariana Petkova; Fernando Ramos; Yolanda Sanz; Roberto Edoardo Villa; Ruud Woutersen; Paul George Brantom; Johannes Westendorf; Jaume Galobart; Paola Manini; Fabiola Pizzo
Journal:  EFSA J       Date:  2022-04-22

4.  Human intestinal microbial metabolism of naringin.

Authors:  Wei Zou; Yulong Luo; Menghua Liu; Si Chen; Sheng Wang; Yichu Nie; Guohua Cheng; Weiwei Su; Kejian Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06-17       Impact factor: 2.441

5.  The Pharmacokinetics, Tissue Distribution, Metabolism, and Excretion of Pinostrobin in Rats: Ultra-High-Performance Liquid Chromatography Coupled With Linear Trap Quadrupole Orbitrap Mass Spectrometry Studies.

Authors:  Xiaoya Sun; Xiaojun Liu; Suiqing Chen
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810

Review 6.  Re-appraising the potential of naringin for natural, novel orthopedic biotherapies.

Authors:  Kristin E Yu; Kareme D Alder; Montana T Morris; Alana M Munger; Inkyu Lee; Sean V Cahill; Hyuk-Kwon Kwon; JungHo Back; Francis Y Lee
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-08       Impact factor: 5.346

7.  A Rapid LC-MS/MS Method for Simultaneous Determination of Ten Flavonoid Metabolites of Naringin in Rat Urine and Its Application to an Excretion Study.

Authors:  Xuan Zeng; Yuying Zheng; Yan He; Wei Peng; Weiwei Su
Journal:  Foods       Date:  2022-01-24

8.  Therapeutic potentials of naringin on polymethylmethacrylate induced osteoclastogenesis and osteolysis, in vitro and in vivo assessments.

Authors:  Nianhu Li; Zhanwang Xu; Paul H Wooley; Jianxin Zhang; Shang-You Yang
Journal:  Drug Des Devel Ther       Date:  2013-12-10       Impact factor: 4.162

9.  UFLC-Q-TOF-MS/MS-Based Screening and Identification of Flavonoids and Derived Metabolites in Human Urine after Oral Administration of Exocarpium Citri Grandis Extract.

Authors:  Xuan Zeng; Weiwei Su; Yuying Zheng; Hong Liu; Panlin Li; Weijian Zhang; Yuting Liang; Yang Bai; Wei Peng; Hongliang Yao
Journal:  Molecules       Date:  2018-04-12       Impact factor: 4.411

10.  Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species.

Authors:  Yang Bai; Wei Peng; Cuiping Yang; Wei Zou; Menghua Liu; Hao Wu; Loudi Fan; Peibo Li; Xuan Zeng; Weiwei Su
Journal:  Front Pharmacol       Date:  2020-03-27       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.